#ESMO20: Autolus provides glimpse of next-generation CAR-T program, showing early positive safety data

Max Gelman

Senior Editor

CAR-T therapies were hailed as a breakthrough when Novartis received the first FDA approval for Kymriah back in 2017. Though highly effective at treating …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

#ESMO20: Autolus provides glimpse of next-generation CAR-T program, showing early positive safety data

Max Gelman

Senior Editor

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

RFK blog: Republican swing votes question Kennedy's vaccine stances

Takeda CEO Christophe Weber to retire in June 2026, Julie Kim to take over

Roche aims for derisked deals and ruthless portfolio cuts in 2025

Sanofi is in the market for M&A, thanks to ‘strong’ balance sheet

Cargo Therapeutics cuts lead CAR-T program, 50% of staff

Why the premier recruitment agency in the world is giving up recruiting, and sponsors should, too

#ES­MO20: Au­to­lus pro­vides glimpse of next-gen­er­a­tion CAR-T pro­gram, show­ing ear­ly pos­i­tive safe­ty da­ta

Senior Editor

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

#ESMO20: Autolus provides glimpse of next-generation CAR-T program, showing early positive safety data